Physician
Lee-Wood, Russell
Lee-Wood, Russell was paid $399K by Medicaid between Jul 2020 and Oct 2024, across 27 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 31% of everything it billed.
33Billing provider infoLEE-WOOD, RUSSELL
SAINT CLAIRSVILLE, OH 43950
SAINT CLAIRSVILLE, OH 43950
33aNPI1619928488assigned 05/15/2006
33bProvider typeFamily Medicine Physician
28Total paid$399K
24GClaims13,014
24DCodes billed27
24AFirst – last monthJul 2020 – Oct 2024
Compared with peers
Next to other Family Medicine Physician providers in Ohio
Rank by total paid#119 of 739
Median peer was paid$30K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,173 | $27K | |
| 2021 | 4,439 | $164K | |
| 2022 | 3,291 | $116K | |
| 2023 | 2,438 | $65K | |
| 2024incomplete | 673 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 31% | 3,296 | 2,523 | $123K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 1,189 | 1,057 | $72K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 17% | 1,970 | 1,199 | $68K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 11% | 532 | 410 | $43K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.1% | 524 | 430 | $33K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.0% | 605 | 537 | $16K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.7% | 155 | 127 | $15K |
| 80305 | 2.4% | 1,431 | 1,126 | $10K | |
| 81025 | <1% | 760 | 540 | $3K | |
| 80361 | <1% | 210 | 149 | $2K | |
| 80363 | <1% | 211 | 150 | $2K | |
| 80306 | <1% | 277 | 222 | $2K |
15 more codes
| 80346 | <1% | 93 | $1K | |
| 80348 | <1% | 215 | $1K | |
| 80356 | <1% | 189 | $1K | |
| 80349 | <1% | 200 | $1K | |
| 80365 | <1% | 212 | $1K | |
| 80354 | <1% | 208 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 79 | $1K |
| 80358 | <1% | 173 | $1K | |
| 80324 | <1% | 126 | $923.08 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $698.90 |
| 80360 | <1% | 96 | $692.79 | |
| 80355 | <1% | 80 | $539.00 | |
| 80359 | <1% | 66 | $462.00 | |
| 80373 | <1% | 63 | $318.61 | |
| 80362 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.